![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/praluent/jcr_content--3--w-overlay.jpg/jcr:content/jcr_content%20(3)%20w%20overlay.jpg)
Profile
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/praluent/suliqua_icon1_1.png0/jcr:content/suliqua_icon1_1.png)
Efficacy
Praluent® is associated with a reduction in major adverse cardiovascular events in the ODYSSEY OUTCOMES CVOT2
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/admelog_icon2_1.jpg/jcr:content/admelog_icon2_1.jpg)
Flexibility of dose
Praluent® offers different dosing options to suit your patient1
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/praluent/toujeo_icon_2-modified.png1/jcr:content/toujeo_icon_2-modified.png)
Safety Profile
Praluent® offers a favourable long-term safety and tolerability profile demonstrated over 5 years in ODYSSEY OUTCOMES1,2
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/praluent/suliqua_icon1_1.png0/jcr:content/suliqua_icon1_1.png)
Efficacy
Praluent® is associated with a reduction in major adverse cardiovascular events in the ODYSSEY OUTCOMES CVOT2
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/admelog_icon2_1.jpg/jcr:content/admelog_icon2_1.jpg)
Flexibility of dose
Praluent® offers different dosing options to suit your patient1
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/praluent/toujeo_icon_2-modified.png1/jcr:content/toujeo_icon_2-modified.png)
Safety Profile
Praluent® offers a favourable long-term safety and tolerability profile demonstrated over 5 years in ODYSSEY OUTCOMES1,2
References
1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed October 2023
2. Schwartz G, et al. N Engl J Med 2018;379:2097–2107.
Indication, Mechanism of Action and Administration
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/praluent/dislipemias.jpg/jcr:content/dislipemias.jpg)
Indication
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/praluent/thumbnail-rosuvastatina-ezetimiba-hipercolesterolemia.jpg0/jcr:content/thumbnail-rosuvastatina-ezetimiba-hipercolesterolemia.jpg)
Mechanism of Action
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/praluent/reduccion-riesgo-cardiovascular-alirocumab.png/jcr:content/reduccion-riesgo-cardiovascular-alirocumab.png)
Administration
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/praluent/dislipemias.jpg/jcr:content/dislipemias.jpg)
Indication
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/praluent/thumbnail-rosuvastatina-ezetimiba-hipercolesterolemia.jpg0/jcr:content/thumbnail-rosuvastatina-ezetimiba-hipercolesterolemia.jpg)
Mechanism of Action
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/praluent/reduccion-riesgo-cardiovascular-alirocumab.png/jcr:content/reduccion-riesgo-cardiovascular-alirocumab.png)
Administration
Expert Hub Videos
Resources include links to videos from Dr Derek Connolly (Consultant Cardiologist, Birmingham UK) discussing topics such as recommended guidance, current clinical trials and peer-2-peer sharing of clinical practice.
Lipid Optimization in ACS patients
In the following video Dr Connolly discusses the evidence for LDL-C causality, the difference between high risk and very high risk patients and the reasons why a post-ACS patient should be screened for lipid optimisation.
The Intensive Lipid-Lowering Approach
In the following video Dr Connolly explains the intensive lipid-lowering therapy approach in high and very high risk ASCVD patients and why this is needed.
Implementing the Intensive Lipid-Lowering Approach
In the following video Dr Connolly discusses implementing the intensive lipid-lowering therapy approach in clinical practice.
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/praluent/MicrosoftTeams-image--2-.jpg4/jcr:content/MicrosoftTeams-image%20(2).jpg)
MAT-XU-2204604 (v4.0) Date of Preparation: October 2023